News
GlobalData on MSN9h
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
Zacks.com on MSN1d
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback